ExThera Medical Corporation is developing revolutionary medical devices that address unmet clinical needs for the treatment of bloodstream infections and pathogen-reduction.

Based in Martinez, California with an office in the Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative, single-use blood filters capable of capturing a broad range of bacteria, viruses, parasites, toxins and other sepsis mediators.

ExThera was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. The company’s first product, the Seraph® 100 Microbind® Affinity Blood Filter, is CE Marked and commercially available in Europe.

The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military use. ExThera also intends to develop, oncology, cardiovascular and diagnostic applications of its technology.



Bloodstream infections are a global health issue and are increasing in incidence despite significant efforts to find effective treatments. If not identified and treated early, these infections can cause serious illness by progressing to sepsis and septic shock with organ damage or organ failure and death.



Events not available


ICU Management

Fresenius Medical Care Expands Critical Care Offering With ExThera Medical’s Seraph 100 Adsorber

2021 07 Jan

Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and... Read more

ICU Management

Michael Porter Of Harvard Business School Has Joined The Board Of Directors Of Exthera Medical

2020 29 Sep

Michael Porter, Ph.D., has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood. ExThera’s  Seraph® 100 Microbind® Affinity Blood Filter  (Seraph 100) has a CE Mark in Europe for the treatment... Read more

ICU Management

DOD to Fund a Clinical Trial of COVID-19 Treatment with ExThera’s Seraph 100 Blood Filter

2020 09 Jun

After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled... Read more

ICU Management

FDA Grants ExThera’s Seraph-100 Blood Filter Emergency Use Authorization for COVID-19

2020 17 Apr

After promising COVID-19 treatments in Germany, France, Italy, Spain and the USA, ExThera Medical ’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has been granted Emergency Use Authorization by the Food and Drug Administration (FDA). This approval comes soon after first use of the device to treat COVID-19 patients in Europe and in... Read more

ICU Management

ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients

2020 26 Mar

Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA. Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical... Read more

Jobs not available


    Catalogue not available

757 Arnold Drive Suite B, Martinez,
United States
(925) 839 -2060

White Papers - Case Studies

Not available



Not available


Not available


Why use this device on COVID 19 patients?
Seraph 100 binds SARS-CoV-2 and removes it from the blood. It has been shown to also remove inflammatory markers such as IL-6. Other inflammatory markers that have correlated to poor outcome such as d-dimers and Ferritin have decreased during and after treatment. Stabilization of blood pressure has also been reported and reduction in the need for vasopressors. This allows additional time for supportive care while reducing the source of inflammation and preventing further damage caused by the pathogen.

Are there additional applications for this device?
Seraph 100 has broad applications for the safe reduction of drug-susceptible and drug-resistant pathogens that are in the bloodstream. Secondary infections from other sources are a known complication of COVID-19.

How does it work?
Seraph 100 is a broad spectrum, anti-thrombogenic hemoperfusion device. Please watch the animation about how it works:


How do I use the device?
The Seraph 100 has standard luer lock fittings and be used with most standard blood pumps or hemofiltration devices at a blood flow rate ranging from 100-350 mL/min. Please consult the Instructions for Use for additional details.

Users in Europe
Please read the information sheet to learn more about the device and how to order it.

Users in United States
Please read the information sheet to learn more about the device and how to order it.
For FDA guidance on the use of Seraph 100 on COVID-19 patients, please follow the links below:

Find ExThera Medical in Social Media